Nuvectis Pharma Inc is a clinical-stage biopharmaceutical company that focuses on the treatment of serious unmet medical needs in oncology. The company is committed to developing innovative and effective cancer therapies that can improve the lives of patients.
Operating in the healthcare sector, Nuvectis’ lead product, NXP800, is a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers. It also has a pipeline of other promising oncology drug candidates in development.
Keep up to date on the latest share price changes by adding NVCT stock to your eToro watchlist.